Ballentine Partners LLC Cuts Holdings in Repligen Co. (NASDAQ:RGEN)

Ballentine Partners LLC lessened its stake in shares of Repligen Co. (NASDAQ:RGEN) by 35.7% during the 2nd quarter, Holdings Channel reports. The fund owned 1,702 shares of the biotechnology company’s stock after selling 947 shares during the period. Ballentine Partners LLC’s holdings in Repligen were worth $215,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. YHB Investment Advisors Inc. purchased a new stake in shares of Repligen during the 1st quarter worth $26,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the second quarter valued at about $33,000. Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter. Principal Securities Inc. purchased a new position in shares of Repligen in the 4th quarter worth approximately $48,000. Finally, Rothschild Investment LLC bought a new position in shares of Repligen during the 2nd quarter worth approximately $57,000. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $141.93 on Friday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The company’s 50 day moving average is $144.61 and its 200 day moving average is $157.83. The company has a market cap of $7.95 billion, a PE ratio of 568.58, a price-to-earnings-growth ratio of 4.35 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the company posted $0.53 earnings per share. The firm’s revenue was down 3.2% compared to the same quarter last year. On average, sell-side analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on RGEN shares. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and decreased their price objective for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Finally, Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.